Wird geladen...
Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death (PD)-1 receptor. It significantly increases the overall survival in patients with locally advanced or metastatic urothelial cancer. However, its administration may induce serious immune-related adverse effec...
Gespeichert in:
| Veröffentlicht in: | eNeurologicalSci |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082602/ https://ncbi.nlm.nih.gov/pubmed/32211521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ensci.2020.100236 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|